Brazil Has Enough Infection Data to Study Sinovac Vaccine

Brazilian authorities have gathered enough infection data from a late-stage trial of China’s Sinovac Biotech experimental vaccine, and expect to have interim results on its efficiency in the first two weeks of December.

Brazilian authorities have gathered enough infection data from a late-stage trial of China’s Sinovac Biotech experimental vaccine, and expect to have interim results on its efficiency in the first two weeks of December.

During a Tuesday morning press conference in capital Brasilia, director of Butantan biomedical research institute Dimas Covas said that trial organizers have 74 confirmed cases among its trial participants, above the 61 initial milestone set for interim efficiency analysis. 

Convas also told local reporters that an independent committee is likely to release the efficiency results in the first two weeks of December based on its analysis of the data. Butantan is the only institute in Brazil that authorities allowed to run the late-stage trial of the Sinovac vaccine.

The news comes as UK’s AstraZeneca Plc on Monday joined its US rivals Pfizer and Moderna and Russia in announcing positive results in pivotal trials, raising hopes that the world would soon have successful vaccines to end the pandemic.

Covas also said that Brazil’s health ministry now has all the data needed to include Coronavac in the national program, while São Paulo Health Secretary Jean Gorinchteyn said on Monday night it expected Brazil’s regulator to approve the use of the Sinovac vaccine, CoronaVac, by January 2021.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.